Fig. 6

The dose and percent change of methotrexate during the treatment failure-free period after TNF inhibitor discontinuation. Methotrexate dose and mean percent change during the treatment failure-free period post-TNF inhibitor discontinuation for the Mono (left bar and blue-filled square) and Combi (right bar and orange-filled circle) groups are shown. Error bars indicate standard error. Methotrexate doses decreased over time in both groups, with a significantly higher proportion of patients receiving 6 mg/week or less in the combi group (p = 0.01 by the Fisher exact test). Missing methotrexate doses due to censoring or treatment-failure events were imputed by the last observation carried forward method. P-values in Fig. 3B for the interaction effect of adding tacrolimus on the change in methotrexate dose over time were estimated by a mixed-effects model adjusted for gender, baseline age, and methotrexate dose